Resumen
Triple-negative breast cancer (TNBC), the most aggressive and heterogenous type of cancer, lacks the expression of hormones like estrogen, progesterone, and human epidermal growth receptor-2, making chemotherapy the only treatment regimen against TNBC. It was further observed that chemotherapy leads to off-site toxicity and chemoresistance, decreasing anticancer activity. Therefore, to overcome the problem faced during chemotherapy, and to address the heterogeneity of TNBC, targeted therapy emerged based on the molecular profiling of TNBC. Such a scenario further encouraged the acceptance of biomarkers as some of the targeting moieties for effective and precise TNBC therapy. Several biomarkers are used as targets for the precision therapy in TNBC, including EGFR, VGFR, TP53, interleukins, insulin-like growth factor binding proteins, c-MET, androgen receptor, BRCA1, glucocorticoid, PTEN, ALDH1, etc. Additionally, nanoparticles were employed as parts of a multifunctional platform to deliver the therapeutics to the target site with increased precision.